Fms-like tyrosine kinase 3 (FLT3) is a tyrosine kinase that is expressed in early hematopoietic progenitor cells, including CD34+ cells.1,2 Binding the FLT3 ligand activates multiple cell signaling pathways, including proliferation and survival in early blood cells.2
FLT3 is overexpressed in leukemic blast cells in >70% of patients with acute myeloid leukemia (AML), irrespective of CD34+ status, which suggests that FLT3 plays a key role in the survival or proliferation of leukemic blast cells.1,3
Therapies targeting FLT3 may be a novel therapeutic approach for treating AML.
Search our clinical trials.
CD: cluster of differentiation.
1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-1542.2. National Institute of Health. FLT3 gene. https://ghr.nlm.nih.gov/gene/FLT3. Accessed 4/9/2019. 3. Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996;87(3):1089-1096.